LeafCann Group has received its Australian cannabis research and medicinal cannabis (cultivation) licences from the Australian Office of Drug Control.
Combined with its existing manufacturing licence, LeafCann now holds a complete set of licences and plans to fulfil its ambition of providing high quality medicines using its ‘seed to sale’ capabilities.
“This is such an exciting moment for the whole organisation,” said LeafCann Group CEO Elisabetta Faenza.
“The next 12-18 months are going to be extremely exciting as we rollout our detailed plans and turn these licences into a business that produces person-centred, precision medicines for Australian patients, creating exceptional value for our customers, staff and investors.”
Leafcann Group Chief Scientist Jaroslav Boublik said, “I’m very pleased that LeafCann Group now holds all three ODC cannabis licences, as this clears the way for execution of the plans we have been developing since the founding of the companies.
“We now look forward to making a significant contribution to the growth of a robust and vibrant medicinal cannabis industry in Australia, and providing patients with new, innovative medicines for a range of ailments,” said Dr Boublik.
LeafCann Group Chairman Ilario Faenza added, “The granting of these additional licences for our first integrated Australian facility, LeafCann Innovate, is a significant milestone for the company and will enable LeafCann to finalise the upgrade of the existing facility and commence operations.”
LeafCann will use its Adelaide-based facility to conduct its initial research, cultivation and manufacturing operations, expected to be fully operational by the beginning of 2021.
